Breaking News Instant updates and real-time market news.

TBPH

Theravance Biopharma

$29.38

1.24 (4.41%)

, GSK

GlaxoSmithKline

$36.82

0.36 (0.99%)

08:43
02/15/18
02/15
08:43
02/15/18
08:43

Theravance Biopharma reports submission of Trelegy Ellipta study to EMA

Theravance Biopharma (TBPH) reported the submission of the IMPACT study data to the European Medicines Agency as part of a type II variation to support an expanded label for Trelegy Ellipta in Europe for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease. Trelegy Ellipta is the triple combination therapy of fluticasone furoate, umeclidinium, and vilanterol in a single Ellipta inhaler. If this latest submission is approved, the labeled indication for Trelegy Ellipta would include a wider population of patients with COPD who are at risk of an exacerbation and require triple therapy. Trelegy Ellipta is a product in which Theravance Biopharma has an economic interest in future payments that may be made by GlaxoSmithKline (GSK) or one of its affiliates pursuant to its agreements with Innoviva, formerly Theravance, Inc. Theravance Biopharma is entitled to receive an 85% economic interest in the royalties paid by GSK on worldwide net sales. Theravance Biopharma is not responsible for any costs related to Trelegy Ellipta.

TBPH

Theravance Biopharma

$29.38

1.24 (4.41%)

GSK

GlaxoSmithKline

$36.82

0.36 (0.99%)

  • 25

    Mar

  • 23

    Apr

  • 13

    Nov

TBPH Theravance Biopharma
$29.38

1.24 (4.41%)

08/16/17
EVER
08/16/17
INITIATION
Target $45
EVER
Outperform
Theravance Biopharma initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Theravance Biopharma with an Outperform and a $45 price target.
06/16/17
CANT
06/16/17
INITIATION
Target $55
CANT
Overweight
Theravance Biopharma initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Theravance Biopharma with an Overweight rating and $55 price target.
05/10/17
LEER
05/10/17
NO CHANGE
Target $47
LEER
Outperform
Theravance Biopharma price target raised to $47 from $34 at Leerink
Leerink analyst Geoffrey Porges raised his price target Theravance Biopharma to $47 from $34 after the company reported Q1 financial results and provided an update for investors about its development progress and upcoming milestones. The analyst reiterates an Outperform rating on the shares.
03/29/17
PIPR
03/29/17
NO CHANGE
Target $42
PIPR
Overweight
Mylan news a positive for Theravance, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Mylan's (MYL) complete response letter for its generic version of GlaxoSmithKline's Advair "buys time and will likely preserve some pricing power in the broader respiratory space." This will be important for GSK's commercialization of the closed triple following potential regulatory approval at year end, Schimmer tells investors in a research note. This is also positive for Theravance Biopharma (TBPH), which stands to receive a "meaningful" mid/high single digit royalty on the closed triple, the analyst contends. He reiterates an Overweight rating on Theravance with a $42 price target. The stock is up 49c to $36.47 in afternoon trading.
GSK GlaxoSmithKline
$36.82

0.36 (0.99%)

02/08/18
MSCO
02/08/18
NO CHANGE
MSCO
Equal Weight
Gilead Biktarvy approval, Glaxo patent suit not surprising, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said investors expected Gilead (GILD) to receive FDA approval for its once-daily single tablet regimen to treat HIV-1 infection, now named Biktarvy, so he would expect limited impact on the stock from the news. He also said GlaxoSmithKline's (GSK) filing of patent infringement litigation alleging that Biktarvy infringes on ViiV's dolutegravir is not a surprise given prior comments by GSK and he would expect this to work through the courts. Harrison, who added that Biktarvy's clean label is a positive, keeps an Equal Weight rating on Gilead shares.
01/22/18
WELS
01/22/18
NO CHANGE
WELS
Underperform
Teva can't afford more pipeline setbacks, says Wells Fargo
After Teva (TEVA) reported that its Phase 3 registration study evaluating subcutaneously administered reslizumab in a pre-filled syringe did not meet its primary endpoint, Wells Fargo analyst David Maris said he believes this puts Teva at a disadvantage versus peers AstraZeneca (AZN) and GlaxoSmithKline (GSK) at a time when Teva cannot afford more pipeline setbacks. Subcutaneous reslizumab was not a major focus, but the news is still "another disappointment," said Maris, who keeps an Underperform rating on Teva shares.
01/22/18
WBLR
01/22/18
NO CHANGE
WBLR
Outperform
Dynavax has sold off 30% since Heplisav approval, says William Blair
Dynavax (DVAX) shares have pulled back about 30% since the U.S. approval of Heplisav, the first and only two-dose hepatitis B vaccine that has demonstrated "superiority in efficacy and comparability" in safety to the standard of care, GlaxoSmithKline's (GSK) Engerix-B, William Blair analyst Katherine Xu tells investors in a research note. The analyst attributes the selloff to Dynavax electing to launch Heplisav on its own and the Street having insufficient confidence in the launch. She believes Heplisav has peak U.S. sales prospects of $600M and "provides a valuation floor." Xu also sees catalysts on the oncology side of the business. She maintains an Outperform rating on Dynavax with a $40 per share fair value estimate.
01/16/18
LEHM
01/16/18
UPGRADE
LEHM
Overweight
GlaxoSmithKline upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Emmanuel Papadakis upgraded GlaxoSmithKline to Overweight from Equal Weight and raised his price target for the shares to GBP 16.50 from GBP 14.50. The analyst believes concerns are now reflected in the valuation and consensus expectations while HIV and shingles offer "sustainable drivers of mid-term growth."

TODAY'S FREE FLY STORIES

OTTW

Ottawa Bancorp

$13.56

-0.14 (-1.02%)

19:02
03/20/19
03/20
19:02
03/20/19
19:02
Hot Stocks
Ottawa Bancorp declares special dividend of 35c per share »

The special dividend will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAZZ

Jazz Pharmaceuticals

$133.73

-1.74 (-1.28%)

18:57
03/20/19
03/20
18:57
03/20/19
18:57
Hot Stocks
Jazz Pharmaceuticals' Sunosi for excessive daytime sleepiness approved by FDA »

Jazz…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

AYI

Acuity Brands

$123.00

-5.53 (-4.30%)

18:52
03/20/19
03/20
18:52
03/20/19
18:52
Upgrade
Acuity Brands rating change  »

Acuity Brands upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Apr

HYAC

Haymaker Acquisition

$11.79

(0.00%)

, OSW

OneSpaWorld

$0.00

(0.00%)

18:47
03/20/19
03/20
18:47
03/20/19
18:47
Hot Stocks
OneSpaWorld says will start trading on Nasdaq March 21 »

OneSpaWorld Holdings…

HYAC

Haymaker Acquisition

$11.79

(0.00%)

OSW

OneSpaWorld

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

$35.07

-0.85 (-2.37%)

, MU

Micron

$40.08

-0.3 (-0.74%)

18:46
03/20/19
03/20
18:46
03/20/19
18:46
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

MLHR

Herman Miller

$35.07

-0.85 (-2.37%)

MU

Micron

$40.08

-0.3 (-0.74%)

WSM

Williams-Sonoma

$56.88

0.09 (0.16%)

SIEN

Sientra

$9.76

0.945 (10.73%)

EB

Eventbrite

$20.09

-0.72 (-3.46%)

GES

Guess

$22.10

-0.41 (-1.82%)

UNIT

Uniti Group

$10.01

0.15 (1.52%)

WEX

Wex

$184.85

-1.465 (-0.79%)

CBMG

Cellular Biomedicine

$18.26

0.38 (2.13%)

FTDR

Frontdoor

$32.10

-2.29 (-6.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 02

    Apr

  • 03

    Apr

  • 28

    May

  • 21

    Mar

  • 21

    Mar

SAGE

Sage Therapeutics

$152.62

-3.46 (-2.22%)

18:39
03/20/19
03/20
18:39
03/20/19
18:39
Hot Stocks
Sage Therapeutics CEO: Postpartum depression is a medical issue »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$174.38

-1.39 (-0.79%)

18:27
03/20/19
03/20
18:27
03/20/19
18:27
Recommendations
Nvidia analyst commentary  »

Nvidia to overcome…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CURLF

Curaleaf Holdings

$0.00

(0.00%)

, CVS

CVS Health

$56.17

-0.93 (-1.63%)

18:24
03/20/19
03/20
18:24
03/20/19
18:24
Periodicals
CVS to start selling CBD products in partnership with Curaleaf, Bloomberg says »

Curaleaf (CURLF) said…

CURLF

Curaleaf Holdings

$0.00

(0.00%)

CVS

CVS Health

$56.17

-0.93 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

PETQ

PetIQ

$29.87

0.91 (3.14%)

18:23
03/20/19
03/20
18:23
03/20/19
18:23
Hot Stocks
PetIQ CEO: We are totally transparent about our price model »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

T

AT&T

$30.51

-0.19 (-0.62%)

18:21
03/20/19
03/20
18:21
03/20/19
18:21
Periodicals
AT&T CEO: Huawei makes it hard for carriers to shift suppliers, Reuters says »

AT&T CEO Randall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 24

    Apr

  • 26

    Apr

  • 07

    May

  • 20

    May

SGSOY

SGS SA

$0.00

(0.00%)

18:19
03/20/19
03/20
18:19
03/20/19
18:19
Downgrade
SGS SA rating change  »

SGS SA downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLX

Clorox

$155.94

-0.93 (-0.59%)

, RBGLY

Reckitt Benckiser

$0.00

(0.00%)

18:16
03/20/19
03/20
18:16
03/20/19
18:16
Hot Stocks
Clorox files false advertising lawsuit against Reckitt Benckiser »

The Clorox Company (CLX)…

CLX

Clorox

$155.94

-0.93 (-0.59%)

RBGLY

Reckitt Benckiser

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

BA

Boeing

$376.41

2.54 (0.68%)

18:09
03/20/19
03/20
18:09
03/20/19
18:09
Periodicals
Boeing pushes flight test to International Space Station to August, Reuters says »

Boeing has postponed by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 28

    May

CE

Celanese

$101.04

0.08 (0.08%)

18:02
03/20/19
03/20
18:02
03/20/19
18:02
Hot Stocks
Celanese increases acetyl intermeditates prices »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

FTDR

Frontdoor

$32.10

-2.29 (-6.66%)

17:58
03/20/19
03/20
17:58
03/20/19
17:58
Syndicate
Frontdoor 16.73M share Secondary priced at $30.00 »

JPMorgan and Goldman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

LEVI

Levi Strauss

$0.00

(0.00%)

17:57
03/20/19
03/20
17:57
03/20/19
17:57
Syndicate
Levi Strauss 36.667M share IPO priced at $17.00 »

The deal priced above its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

17:55
03/20/19
03/20
17:55
03/20/19
17:55
Conference/Events
William Blair healthcare/biotech analysts to hold a dinner meeting »

Analysts meet with…

JBLU

JetBlue

$16.31

-0.32 (-1.92%)

17:50
03/20/19
03/20
17:50
03/20/19
17:50
Periodicals
Suit: JetBlue pilots sexually assaulted female airline workers, NY Post says »

According to a report…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.14

1.57 (0.84%)

, NWS

News Corp

$12.64

0.02 (0.16%)

17:50
03/20/19
03/20
17:50
03/20/19
17:50
Periodicals
Apple reaches deal with WSJ over Apple News service, 9to5Mac says »

Apple (AAPL) has made a…

AAPL

Apple

$188.14

1.57 (0.84%)

NWS

News Corp

$12.64

0.02 (0.16%)

NWSA

News Corp.

$12.61

0.07 (0.56%)

NYT

New York Times

$33.36

-0.62 (-1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

MAR

Marriott

$123.65

-2.09 (-1.66%)

, CVS

CVS Health

$56.17

-0.93 (-1.63%)

17:47
03/20/19
03/20
17:47
03/20/19
17:47
Hot Stocks
Marriott appoints Margaret McCarthy to Board of Directors »

The Board of Directors of…

MAR

Marriott

$123.65

-2.09 (-1.66%)

CVS

CVS Health

$56.17

-0.93 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Apr

BA

Boeing

$376.41

2.54 (0.68%)

17:28
03/20/19
03/20
17:28
03/20/19
17:28
Hot Stocks
Boeing awarded $4.04B Navy contract modification for delivery of 78 F/A-18s »

Boeing has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 28

    May

WOR

Worthington

$36.81

-0.175 (-0.47%)

17:24
03/20/19
03/20
17:24
03/20/19
17:24
Hot Stocks
Worthington announces additional 6.6M share repurchase plan »

The board of directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

MU

Micron

$40.08

-0.3 (-0.74%)

17:24
03/20/19
03/20
17:24
03/20/19
17:24
Hot Stocks
Micron says it is idling DRAM capacity »

Says wants to bring…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 28

    May

T

AT&T

$30.51

-0.19 (-0.62%)

, CMCSA

Comcast

$39.48

-0.35 (-0.88%)

17:21
03/20/19
03/20
17:21
03/20/19
17:21
Periodicals
AT&T, Comcast partnering to fight robocalls, Verge says »

AT&T (T) and Comcast…

T

AT&T

$30.51

-0.19 (-0.62%)

CMCSA

Comcast

$39.48

-0.35 (-0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 24

    Apr

  • 25

    Apr

  • 26

    Apr

  • 07

    May

  • 20

    May

RAVN

Raven

$38.67

-0.05 (-0.13%)

17:21
03/20/19
03/20
17:21
03/20/19
17:21
Earnings
Raven reports Q4 EPS 8c, one estimate 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.